ImmuPharma plc (LON:IMM – Get Free Report) shares rose 42.2% on Monday . The stock traded as high as GBX 5.60 ($0.07) and last traded at GBX 5.60 ($0.07). Approximately 25,452,426 shares changed hands during mid-day trading, an increase of 27% from the average daily volume of 20,003,797 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Price Performance
The business’s fifty day simple moving average is GBX 1.75 and its 200 day simple moving average is GBX 1.73. The stock has a market cap of £23.30 million, a price-to-earnings ratio of -559.60 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- What to Know About Investing in Penny Stocks
- The 3 Biggest M&A Stock Opportunities for 2025
- Business Services Stocks Investing
- A Pivotal Moment for the Consumer Discretionary Sector
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- How Mixed Analyst Opinions Are Shaping Apple Stock’s Outlook
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
